Autolus Therapeutics plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
26.3%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$149.8Mnext fiscal year
FY EPS (est.)
-$0.79next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Updates | 5 Nov 2026 |
| Q4 and Full Year 2026 Financial Results and Business Updates | 25 Mar 2027 |
Monitoring Framework
Key Performance Indicators
AUCATZYL Net Product Revenue Quarterly26.2MTarget: $120 million to $135 million
Cash, Cash Equivalents, and Marketable Securities Quarterly229.4MTarget: Sufficient to fund operations into Q4 2027
Gross Profit Margin (ALL Business) Quarterly1.6MTarget: Continued positive gross margin and expansion throughout 2026
Watch Items
- BOBCAT Phase 1 trial initial clinical data in progressive multiple sclerosis (MS)Trigger: Initial data readout expected by year-end 2026Action: Evaluate safety, tolerability, and preliminary efficacy of obe-cel in progressive MS patients to support progression to Phase 2.
- ALARIC Phase 1 trial initial clinical data in light-chain amyloidosis (AUTO8)Trigger: Initial data readout expected by year-end 2026Action: Assess safety and preliminary efficacy of AUTO8 to determine next clinical development steps.
- Strategic cost reduction and workforce restructuring initiativeTrigger: 13% workforce reduction largely complete by Q3 2026Action: Monitor realization of the projected $15 million in annualized operating expense savings starting in 2027.
Research as of 19 Jun 2026